Recordati
- Company typePublic
- Founded1926
- HeadquartersMaslak
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Recordati firmographics
Firmographics- Name
- Recordati
- Legal name
- Recordati İlaç Sanayi ve Ticaret Anonim Şirketi
- Website
- https://recordati.com.tr
- Company type
- Public
- Founded year
- 1926
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Ownership category
- akta.pro rank
Recordati industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where Recordati is headquartered
LocationHeadquarters
- HQ city
- Maslak
Offices5 records
Markets served
Recordati business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Recordati generates revenue primarily through the sale of branded pharmaceutical products across cardiovascular, urology, rare diseases, and general healthcare categories. The company sells directly through subsidiaries and via licensing agreements across European markets and Turkey.
- Rare Disease Therapeutics: Specialty pharmaceutical products for rare diseases including Isturisa for Cushing's syndrome and Signifor LAR, driving premium pricing and growth in the rare diseases portfolio.
- Licensing and Distribution: Revenue from licensing products to distribution partners in various countries and through licensing in deals such as Eligard distribution rights in Europe.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
Recordati product offering
Product offeringCore offering
Recordati develops, manufactures, and commercializes pharmaceutical products with concentrated R&D investment in cardiovascular, urology, and rare disease therapeutic areas. The company operates four GMP-certified production facilities across Italy, France, Turkey, and Spain, producing approximately 190 million packages annually in solid oral, liquid, topical, and injectable formulations. Its product range spans prescription drugs for hypertension, hyperammonemia, Cushing's syndrome, prostate cancer, acne, and other conditions, sold via subsidiaries and licensing partners across Europe, Turkey, Central/Eastern Europe, and selected markets such as China.
Product overview
Recordati is an international Italian pharmaceutical group established in 1926, operating across major European countries and Turkey. The company develops, manufactures, and commercializes a broad portfolio of prescription and self-medication pharmaceutical products. R&D investments are concentrated in cardiovascular, urology, and rare diseases therapeutic areas. The product portfolio includes treatments spanning multiple therapeutic categories including cardiovascular drugs (Alipza®, Lercadip®, Zanipress®), urology medications (Urorec®, Kentera®, Ürispas®), rare disease drugs (Signifor®, Carbaglu®, Isturisa®), anti-infectives (Ciprasid®, Levonidin®, Cleanomisin®), CNS medications (Stilizan®, Cabral®), dermatology products (Aknetrent®, Terminus®), and consumer health remedies (Algesal®, Casenlax®, Kreval®). Manufacturing capabilities include solid oral, liquid, and topical formulations across facilities in Italy, France, Turkey (Çerkezköy), and Spain (Zaragoza).
Differentiator
Problem solved
Functional benefit
Brands
- Eligard: Gonadotropin releasing hormone analogue injection for prostate cancer treatment
- Signifor
- Carbaglu
- Isturisa
- Lercadip
- Kentera
Products and services
- Aknetrent Systemic acne treatment retinoid containing isotretinoin, available in 10mg and 20mg soft capsule formulations for patients requiring oral acne therapy.
- Algesal Topical analgesic ointment containing diethylamine salicylate indicated for musculoskeletal discomfort and inflammation in adult patients.
- Alipza Lipid-modifying agent containing pitavastatin calcium, an HMG-CoA reductase inhibitor, available as 1mg, 2mg, and 4mg film-coated tablets for hyperlipidemia management.
- Carbaglu Orphan drug containing carglumic acid 200mg dispersible tablets for treatment of hyperammonemia caused by N-acetylglutamate synthase (NAGS), isovaleric acidemia (IVA), methylmalonic acidemia (MMA), and propionic acidemia (PA).
- Signifor Rare disease treatment for Cushing's Disease containing pasireotide diaspartate, available as 0.3mg, 0.6mg, and 0.9mg subcutaneous injection solutions.
- Eligard Gonadotropin-releasing hormone analogue containing leuprorelin acetate for prostate cancer treatment, available as 22.5mg and 45mg subcutaneous injection formulations.
- Citrafleet Laxative preparation containing sodium picosulfate, light magnesium oxide, and anhydrous citric acid in oral powder sachets for constipation and bowel preparation before diagnostic procedures.
- Kentera Transdermal patch containing oxybutynin at 3.9mg/24 hours for urinary antispasmodic treatment of overactive bladder.
- Urorec Urological alpha-adrenoceptor antagonist containing silodosin for benign prostatic hyperplasia treatment, available as 4mg and 8mg capsules.
- Lercadip Selective calcium channel blocker containing lercanidipine hydrochloride for hypertension treatment, available as 10mg and 20mg film-coated tablets.
- Zanipress Combination antihypertensive containing enalapril maleate and lercanidipine hydrochloride in 20mg/10mg and 20mg/20mg film-coated tablets for hypertension treatment.
- Isturisa Cushing's syndrome therapy included in Recordati's rare diseases portfolio, driving premium pricing and portfolio growth.
Quantifiable outcome
- 8.3% revenue growth to €2.62 billion in 2025
- +1 more outcomes
Companies that use Recordati
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Recordati technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Recordati partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- China Regulatory AuthoritiescoreRecordati received approval for Signifor LAR in China in 2025, marking a significant entry into the Chinese rare disease market. This represents Recordati's strategic move to establish presence in China as a co-development ground rather than merely an export market.
- Güney Bağımsız Denetim ve Serbest Muhasebeci Mali Müşavirlik A.Ş.minorGüney Bağımsız Denetim is the independent audit firm for Recordati İlaç Sanayi ve Ticaret A.Ş., located at Maslak Mah. Eski Büyükdere Cad. Orjin Maslak Plaza Sarıyer Istanbul.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Recordati competitors and assessment
Company assessmentDirect peers
- Ipsen: French specialty pharma with strong rare disease, oncology, and neurology franchises — directly comparable specialty/rare-disease model with European commercial base.
- Zambon: Italian multinational pharma focused on specialty areas including CNS and rare diseases — comparable as a mid-sized European specialty pharma with branded commercialization model.
- UCB: Belgian specialty biopharma with strong neurology and immunology franchises — comparable European specialty pharma with branded, high-margin product model and similar international footprint.
- Chiesi Farmaceutici: Italian private specialty pharmaceutical group with strong rare disease (e.g., lysosomal storage disorders) and respiratory franchises — directly comparable as another mid-sized European specialty/rare-disease pharma with branded portfolio model.
- Swedish Orphan Biovitrum (Sobi): Swedish specialty biopharma focused on rare diseases and specialty care — directly comparable as a European mid-cap rare-disease pure play with orphan-drug commercial model.
- Almirall: Spanish specialty pharma focused on dermatology and specialty care, listed in Spain — comparable as a European mid-cap specialty pharma with branded product model and similar EU commercial footprint.
- H. Lundbeck: Danish specialty pharma focused on CNS and rare neurological disorders — comparable as a European mid-cap branded specialty pharma with concentrated therapeutic focus.
- Menarini Group: Privately held Italian pharma with diversified branded portfolio across cardiology, oncology, and consumer health — comparable geographic base (Italy + international) and similar specialty/primary care mix.
- Stada Arzneimittel: European specialty and generics pharma with branded focus and strong presence in Germany and Central/Eastern Europe — comparable portfolio mix and geographic overlap with Recordati's CEE and Turkish operations.
Broad incumbents
- Takeda Pharmaceutical (Shire franchise): Global pharma whose Shire acquisition brought a large rare-disease franchise overlapping with Recordati's rare disease portfolio — broad incumbent competing in the same orphan disease categories.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Recordati social profiles
Digital presenceRecordati financial estimates
Financial estimateRevenue estimate
Valuation estimate
Recordati leadership team
Management profileNumber of profiles
Profiles2 records
Recordati subsidiaries and ownership
Company hierarchySubsidiaries3 records
Recordati funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Recordati M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Recordati
What does Recordati do?
Recordati develops, manufactures, and commercializes pharmaceutical products with concentrated R&D investment in cardiovascular, urology, and rare disease therapeutic areas. The company operates four GMP-certified production facilities across Italy, France, Turkey, and Spain, producing approximately 190 million packages annually in solid oral, liquid, topical, and injectable formulations. Its product range spans prescription drugs for hypertension, hyperammonemia, Cushing's syndrome, prostate cancer, acne, and other conditions, sold via subsidiaries and licensing partners across Europe, Turkey, Central/Eastern Europe, and selected markets such as China.
Is Recordati a public or private company?
Recordati is a public company. It is classified as public and is currently operating.
When was Recordati founded?
Recordati was founded in 1926. It employs 501 to 1,000 people.
Where is Recordati based?
Recordati is headquartered in Maslak.
How does Recordati make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are rare Disease Therapeutics and licensing and Distribution.
Who are Recordati's main competitors?
Direct peers on record are Ipsen, Zambon, UCB, Chiesi Farmaceutici, Swedish Orphan Biovitrum (Sobi), Almirall, H. Lundbeck, Menarini Group and Stada Arzneimittel. Takeda Pharmaceutical (Shire franchise) is listed as a broad incumbent.
Does Recordati have an API?
No public API is recorded for Recordati.
What industry is Recordati in?
Recordati's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.